Report: Pfizer coronavirus vaccine could be available for kids under 5 in February


The Pfizer-BioNTech coronavirus vaccine could become available for children younger than 5 by the end of February, people familiar with the matter told The Washington Post on Monday. This would be the first vaccine made available for the age group in the United States.
The companies are expected to soon submit a request to the Food and Drug Administration for emergency-use authorization of the vaccine in kids 6 months to 5 years old, the Post reports. Once the FDA receives the application, regulators will begin reviewing the trial data on the two-shot regimen; data on a third shot won't be available until the end of March, at the earliest. The FDA's outside advisers will likely meet on the authorization request in mid-February, the Post reports.
Pfizer and BioNTech shared in December that two doses of its vaccine in 2-, 3-, and 4-year-olds didn't trigger the same type of immune response as seen in teens and adults, but did for children 6 months to 2 years old. During the trial, the kids received two doses of 3-microgram shots — a tenth of the dose given to adults — three weeks apart. Read more at The Washington Post.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
How the civil service works – and why critics say it needs reform
The Explainer Keir Starmer wants to 'rewire' Whitehall, which he has claimed is too 'comfortable in the tepid bath of managed decline'
-
Brexit 'reset' deal: how will it work?
In Depth Keir Stamer says the deal is a 'win-win', but he faces claims that he has 'surrendered' to Brussels on fishing rights
-
Crossword: May 25, 2025
The Week's daily crossword
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr.: A new plan for sabotaging vaccines
Feature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
Unraveling autism: RFK Jr.'s vow to find a root cause
Feature RFK Jr. has vowed to find the root cause of the 'autism epidemic' in months. Scientists have doubts.
-
The sneaking rise of whooping cough
Under the Radar The measles outbreak isn't the only one to worry about
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia